The BioWorld Drug Developers Index underperformed both the Nasdaq Biotechnology Index (NBI) and the Dow Jones Industrial ...

Zip Diagnostics Pty Ltd., Menzies School of Health Research and Axxin Pty Ltd., a Melbourne, Australia-based diagnostic ...

In what represents just the company’s third PCT filing, Houston-based Starling Medical Inc.’s co-founders, Hannah McKenney ...

Rhabdomyosarcoma is an aggressive soft tissue cancer that primarily affects children, accounting for around 7% of all ...

Rebrain SAS's Optimmri platform received European Medical Device Regulation CE mark certification to enable surgeons to ...

Incyte Corp.’s Zynyz (retifanlimab-dlwr) has received another U.S. FDA approval and put some distance between it and a 2021 ...

It’s been a big week for Inozyme Pharma Inc. On the heels of a promising interim readout for phase III-stage enzyme replacement therapy (ERT) candidate INZ-701 in ENPP1 deficiency, the firm agreed to ...

Gene and cell therapies (GCTs) can target the kidney to treat congenital, acute or chronic diseases affecting this organ.

Therini Bio raised an additional $39 million in its series A financing round, bringing the total for the round to $75 million. The capital will be used to advance its fibrin-targeting immunotherapies ...

U.S. Health and Human Services Secretary Robert Kennedy made his first appearance May 14 before the Senate Health, Education, ...

Pharmaceutical Technology Co. Ltd. has discovered compounds acting as diacylglycerol kinase ζ (DGK-ζ) inhibitors reported to be useful for the treatment of cancer.

Gen1e Lifesciences Inc. has disclosed drugs targeting extracellular-regulated kinase (ERK) reported to be useful for the treatment of cancer, inflammatory disorders, autoimmune and lung diseases.